Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the modest introduction of emerging therapies in the bipolar depression market will not compensate for extensive generic erosion of branded agents, resulting in a decrease of just over $1 billion in drug sales through 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Bipolar Depression finds that while physician awareness of bipolar depression is increasing, the severe generic erosion facing the market over the next several years - particularly in the atypical antipsychotic class - will significantly constrain overall growth. Among the key agents that will lose patent exclusivity over the next several years are AstraZeneca's Seroquel, Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify and GlaxoSmithKline's Lamictal. Additionally, while three novel agents are in development for approval to treat bipolar depression - Repligen's RG-2417, Lundbeck's LU-AA34893 and Cephalon's Nuvigil - the introduction of these and other emerging agents will not be enough to sustain market sales. The report finds that considerable opportunity remains for a drug that has benefits in safety and tolerability as compared to currently-approved therapies for bipolar depression, which are associated with considerable metabolic side effects.

The report also finds that while over 8.5 million people suffer from bipolar depression in the seven major markets under study, a significant percentage of cases are often erroneously identified as unipolar depression.

"Even when suffering from a major depressive episode, not all bipolar depression patients are correctly diagnosed," said Sandra Chow, analyst at Decision Resources. "We found that only two-thirds of bipolar depression patients in the United States and one-half of these patients in Europe are correctly diagnosed. Although increasing awareness of bipolar depression among physicians will result in an increase in diagnosis rates and will drive drug sales, this will not be enough to offset the losses caused by generic erosion in the market."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  Decision Resources          Decision Resources, Inc.   Christopher Comfort         Elizabeth Marshall   781-296-2597                781-296-2563   ccomfort@dresources.com     emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

Contact: Christopher Comfort, Decision Resources, +1-781-296-2597,
ccomfort@dresources.com; Elizabeth Marshall, +1-781-296-2563,
emarshall@dresources.com

Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017

View Now